Non-Coding RNAs in Diffuse Large B-Cell Lymphoma

References

• Li S, Young KH, Medeiros LJ. Diffuse large B-cell lymphoma. Pathology. 2018;50(1):74–87. doi:10.1016/j.pathol.2017.09.00629167021
   PubMed Web of Science ®Google Scholar
• Lossos IS, Morgensztern D. Prognostic biomarkers in diffuse large B-cell lymphoma. J Clin Oncol. 2006;24(6):995–1007. doi:10.1200/JCO.2005.02.478616418498
   PubMed Web of Science ®Google Scholar
• Friedberg JW. Relapsed/refractory diffuse large B-cell lymphom. Hematology. 2011;2011:4985–5005. doi:10.1182/asheducation-2011.1.498
   Google Scholar
• Jacobs R, Ghosh N. Conditioning prior to allogeneic hematopoietic stem cell transplants for relapsed/refractory diffuse large B-cell lymphoma-is more actually less? Biol Blood Marrow Transplant. 2020;26(4):e75–e76. doi:10.1016/j.bbmt.2020.02.00232045653
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-Cell lymphoma. N Engl J Med. 2019;380(1):45–56. doi:10.1056/NEJMoa180498030501490
   PubMed Web of Science ®Google Scholar
• Llave C, Xie Z, Kasschau KD, Carrington JC. Cleavage of scarecrow-like mRNA targets directed by a class of arabidopsis miRNA. Science. 2002;297(5589):2053–2056. doi:10.1126/science.107631112242443
   PubMed Web of Science ®Google Scholar
• ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012;489(7414):57–74. doi:10.1038/nature11247.22955616
   PubMed Web of Science ®Google Scholar
• Esteller M. Non-coding RNAs in human disease. Nat Rev Genet. 2011;12(12):861–874. doi:10.1038/nrg307422094949
   PubMed Web of Science ®Google Scholar
• Ghafouri-Fard S, Esmaeili M, Taheri M. Expression of non-coding RNAs in hematological malignancies. Eur J Pharmacol. 2020;875:172976. doi:10.1016/j.ejphar.2020.17297632112777
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–297. doi:10.1016/s0092-8674(04)00045-514744438
   PubMed Web of Science ®Google Scholar
• Bracken CP, Scott HS, Goodall GJ. A network-biology perspective of microRNA function and dysfunction in cancer. Nat Rev Genet. 2016;17(12):719–732. doi:10.1038/nrg.2016.13427795564
   PubMed Web of Science ®Google Scholar
• Getaneh Z, Asrie F, Melku M. MicroRNA profiles in B-cell non-Hodgkin lymphoma. EJIFCC. 2019;30(2):195–214.31263393
   PubMedGoogle Scholar
• Zheng B, Xi Z, Liu R, et al. The function of MicroRNAs in B-Cell development, lymphoma, and their potential in clinical practice. Front Immunol. 2018;9:936. doi:10.3389/fimmu.2018.0093629760712
   PubMed Web of Science ®Google Scholar
• Musilova K, Mraz M. MicroRNAs in B-cell lymphomas: how a complex biology gets more complex. Leukemia. 2015;29(5):1004–1017. doi:10.1038/leu.2014.35125541152
   PubMed Web of Science ®Google Scholar
• Jardin F, Figeac M. MicroRNAs in lymphoma, from diagnosis to targeted therapy. Curr Opin Oncol. 2013;25(5):480–486. doi:10.1097/CCO.0b013e328363def223852382
   PubMed Web of Science ®Google Scholar
• Di Lisio L, Martinez N, Montes-Moreno S, Piris-Villaespesa M, Sanchez-Beato M, Piris MA. The role of miRNAs in the pathogenesis and diagnosis of B-cell lymphomas. Blood. 2012;120(9):1782–1790. doi:10.1182/blood-2012-05-40278422760782
   PubMed Web of Science ®Google Scholar
• Malumbres R, Sarosiek KA, Cubedo E, et al. Differentiation stage-specific expression of microRNAs in B lymphocytes and diffuse large B-cell lymphomas. Blood. 2009;113(16):3754–3764. doi:10.1182/blood-2008-10-18407719047678
   PubMed Web of Science ®Google Scholar
• Hershkovitzrokah O, Geva P, Salmondivon M, Shpilberg O, Libermanaronov S. Network analysis of microRNAs, genes and their regulation in diffuse and follicular B-cell lymphomas. Oncotarget. 2018;9(8):7928–7941. doi:10.18632/oncotarget.2397429487703
   PubMedGoogle Scholar
• Lim EL, Trinh DL, Scott DW, et al. Comprehensive miRNA sequence analysis reveals survival differences in diffuse large B-cell lymphoma patients. Genome Biol. 2015;16(1):18. doi:10.1186/s13059-014-0568-y25723320
   PubMed Web of Science ®Google Scholar
• Zhong H, Xu L, Zhong JH, et al. Clinical and prognostic significance of miR-155 and miR-146a expression levels in formalin-fixed/paraffin-embedded tissue of patients with diffuse large B-cell lymphoma. Exp Ther Med. 2012;3(5):763–770. doi:10.3892/etm.2012.50222969965
   PubMed Web of Science ®Google Scholar
• Sun JR, Zhang X, Zhang Y. MiR-214 prevents the progression of diffuse large B-cell lymphoma by targeting PD-L1. Cell Mol Biol Lett. 2019;24:68. doi:10.1186/s11658-019-0190-931844419
   PubMed Web of Science ®Google Scholar
• Bedewy AML, Elmaghraby SM, Shehata AA, Kandil NS. Prognostic value of miRNA-155 expression in B-cell non-Hodgkin lymphoma. Turk J Haematol. 2017;34(3):207–212. doi:10.4274/tjh.2016.028628148469
   PubMed Web of Science ®Google Scholar
• Go H, Jang JY, Kim PJ, et al. MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma. Oncotarget. 2015;6(17):15035–15049. doi:10.18632/oncotarget.372925909227
   PubMedGoogle Scholar
• Iqbal J, Shen Y, Huang X, et al. Global microRNA expression profiling uncovers molecular markers for classification and prognosis in aggressive B-cell lymphoma. Blood. 2015;125(7):1137–1145. doi:10.1182/blood-2014-04-56677825498913
   PubMed Web of Science ®Google Scholar
• Zhu FQ, Zeng L, Tang N, et al. MicroRNA-155 downregulation promotes cell cycle arrest and apoptosis in diffuse large B-cell lymphoma. Oncol Res. 2016;24(6):415–427. doi:10.3727/096504016X1468503410347328281962
   PubMed Web of Science ®Google Scholar
• Carig VJ, Tzankov A, Flori M, Schmid CA, Bader AG, Müller A. Systemic microRNA-34a delivery induces apoptosis and abrogates growth of diffuse large B-cell lymphoma in vivo. Leukemia. 2012;26(11):2421–2424. doi:10.1038/leu.2012.11022522790
   PubMed Web of Science ®Google Scholar
• Li XD, Li XM, Gu JW, Sun XC. MiR-155 regulates lymphoma cell proliferation and apoptosis through targeting SOCS3/JAK-STAT3 signaling pathway. Eur Rev Med Pharmacol Sci. 2017;21(22):5153–5159. doi:10.26355/eurrev_201711_1383229228427
   PubMed Web of Science ®Google Scholar
• Huang X, Shen Y, Liu M, et al. Quantitative proteomics reveals that miR-155 regulates the PI3K-AKT pathway in diffuse large B-cell lymphoma. Am J Pathol. 2012;181(1):26–33. doi:10.1016/j.ajpath.2012.03.01322609116
   PubMed Web of Science ®Google Scholar
• Pedersen IM, Otero D, Kao E, et al. Onco-miR-155 targets SHIP1 to promote TNFalpha-dependent growth of B cell lymphomas. EMBO Mol Med. 2009;1(5):288–295. doi:10.1002/emmm.20090002819890474
   PubMed Web of Science ®Google Scholar
• Jiang D, Aguiar RC. MicroRNA-155 controls RB phosphorylation in normal and malignant B lymphocytes via the noncanonical TGF-β1/SMAD5 signaling module. Blood. 2014;123(1):86–93. doi:10.1182/blood-2013-07-51525424136167
   PubMed Web of Science ®Google Scholar
• Huskova H, Korecka K, Karban J, et al. Oncogenic microRNA-155 and its target PU.1: an integrative gene expression study in six of the most prevalent lymphomas. Int J Hematol. 2015;102(4):441–450. doi:10.1007/s12185-015-1847-426261072
   PubMed Web of Science ®Google Scholar
• Due H, Schönherz AA, Ryø L, et al. MicroRNA-155 controls vincristine sensitivity and predicts superior clinical outcome in diffuse large B-cell lymphoma. Blood Adv. 2019;3(7):1185–1196. doi:10.1182/bloodadvances.201802966030967394
   PubMed Web of Science ®Google Scholar
• Liu K, Du J, Ruan L. MicroRNA-21 regulates the viability and apoptosis of diffuse large B-cell lymphoma cells by upregulating B cell lymphoma-2. Exp Ther Med. 2017;14(5):4489–4496. doi:10.3892/etm.2017.502129067124
   PubMed Web of Science ®Google Scholar
• Song J, Shao Q, Li C, et al. Effects of microRNA-21 on apoptosis by regulating the expression of PTEN in diffuse large B-cell lymphoma. Medicine. 2017;96(39):e7952. doi:10.1097/MD.000000000000795228953617
   PubMed Web of Science ®Google Scholar
• Kim SW, Ramasamy K, Bouamar H, Lin AP, Jiang D, Aguiar RC. MicroRNAs miR-125a and miR-125b constitutively activate the NF-κB pathway by targeting the tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20). Proc Natl Acad Sci U S A. 2012;109(20):7865–7870. doi:10.1073/pnas22550173
   PubMed Web of Science ®Google Scholar
• Nie K, Zhang T, Allawi H, et al. Epigenetic down-regulation of the tumor suppressor gene PRDM1/Blimp-1 in diffuse large B cell lymphomas: a potential role of the microRNA let-7. Am J Pathol. 2010;177(3):1470–1479. doi:10.2353/ajpath.2010.09129120651244
   PubMed Web of Science ®Google Scholar
• Fan Q, Meng X, Liang H, et al. MiR-10a inhibits cell proliferation and promotes cell apoptosis by targeting BCL6 in diffuse large B-cell lymphoma. Protein Cell. 2016;7(12):899–912.27815824
   PubMed Web of Science ®Google Scholar
• Huang F, Jin Y, Wei Y. MicroRNA-187 induces diffuse large B-cell lymphoma cell apoptosis via targeting BCL6. Oncol Lett. 2016;11(4):2845–2850. doi:10.3892/ol.2016.431327073562
   PubMed Web of Science ®Google Scholar
• Farina FM, Inguscio A, Kunderfranco P, Cortesi A, Elia L, Quintavalle M. MicroRNA-26a/cyclin-dependent kinase 5 axis controls proliferation, apoptosis and in vivo tumor growth of diffuse large B-cell lymphoma cell lines. Cell Death Dis. 2017;8(6):e2890. doi:10.1038/cddis.2017.29128640256
   PubMedGoogle Scholar
• Jia YJ, Liu ZB, Wang WG, et al. HDAC6 regulates microRNA-27b that suppresses proliferation, promotes apoptosis and target MET in diffuse large B-cell lymphoma. Leukemia. 2018;32(3):703–711. doi:10.1038/leu.2017.29929135973
   PubMed Web of Science ®Google Scholar
• Huang Y, Zou Y, Lin L, Ma X, Zheng R. MiR-101 regulates cell proliferation and apoptosis by targeting KDM1A in diffuse large B cell lymphoma. Cancer Manag Res. 2019;11:2739–2746.31040714
   PubMed Web of Science ®Google Scholar
• Song G, Song G, Ni H, et al. Deregulated expression of miR-224 and its target gene: CD59 predicts outcome of diffuse large B-cell lymphoma patients treated with R-CHOP. Curr Cancer Drug Targets. 2014;14(7):659–670. doi:10.2174/156800961466614081821110325146331
   PubMed Web of Science ®Google Scholar
• Zhu D, Fang C, He W, Wu C, Li X, Wu J. MicroRNA-181a inhibits activated B-cell-like diffuse large B-cell lymphoma progression by repressing CARD11. J Oncol. 2019;2019:9832956. doi:10.1155/2019/983295631662757
   PubMed Web of Science ®Google Scholar
• Zhuang H, Shen J, Zheng Z, Luo X, Gao R, Zhuang X. MicroRNA-146a rs2910164 polymorphism and the risk of diffuse large B cell lymphoma in the Chinese Han population. Med Oncol. 2014;31(12):306. doi:10.1007/s12032-014-0306-z25370733
   PubMed Web of Science ®Google Scholar
• Li T, Niu L, Wu L, et al. A functional polymorphism in microRNA-196a2 is associated with increased susceptibility to non-Hodgkin lymphoma. Tumour Biol. 2015;36(5):3279–3284. doi:10.1007/s13277-014-2957-y25501512
   PubMedGoogle Scholar
• Kwanhian W, Lenze D, Alles J, et al. MicroRNA-142 is mutated in about 20% of diffuse large B-cell lymphoma. Cancer Med. 2012;1(2):141–155. doi:10.1002/cam4.2923342264
   PubMed Web of Science ®Google Scholar
• Eis PS, Tam W, Sun L, et al. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci U S A. 2005;102(10):3627–3632. doi:10.1073/pnas.050061310215738415
   PubMed Web of Science ®Google Scholar
• Di Lisio L, Sánchez-Beato M, Gómez-López G, et al. MicroRNA signatures in B-cell lymphomas. Blood Cancer J. 2012;2(2):e57. doi:10.1038/bcj.2012.122829247
   PubMedGoogle Scholar
• Lenze D, Leoncini L, Hummel M, et al. The different epidemiologic subtypes of Burkitt lymphoma share a homogenous microRNA profile distinct from diffuse large B-cell lymphoma. Leukemia. 2011;25:1869–1876. doi:10.1038/leu.2011.15621701491
   PubMed Web of Science ®Google Scholar
• Gebauer N, Thorns C, Bernard V, et al. MicroRNA profiling of low-grade and transformed nodal marginal zone lymphoma reveals a similar signature pattern distinct from diffuse large B cell lymphoma. Acta Haematol. 2015;133(2):214–220. doi:10.1159/00036309625376122
   PubMed Web of Science ®Google Scholar
• Roehle A, Hoefig KP, Repsilber D, et al. MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas. Br J Haematol. 2008;142(5):732–744. doi:10.1111/j.1365-2141.2008.07237.x18537969
   PubMed Web of Science ®Google Scholar
• Culpin RE, Proctor SJ, Angus B, Crosier S, Anderson JJ, Mainou-Fowler T. A 9 series microRNA signature differentiates between germinal centre and activated B-cell-like diffuse large B-cell lymphoma cell lines. Int J Oncol. 2010;37(2):367–376. doi:10.3892/ijo_0000068520596664
   PubMed Web of Science ®Google Scholar
• Fassina A, Marino F, Siri M, et al. The miR-17-92 microRNA cluster: a novel diagnostic tool in large B-cell malignancies. Lab Invest. 2012;92(11):1574–1582. doi:10.1038/labinvest.2012.12922964854
   PubMed Web of Science ®Google Scholar
• Tamaddon G, Geramizadeh B, Karimi MH, Mowla SJ, Abroun S. MiR-4284 and miR-4484 as putative biomarkers for diffuse large B-cell lymphoma. Iran J Med Sci. 2016;41(4):334–339.27365556
   PubMed Web of Science ®Google Scholar
• Lawrie CH, Soneji S, Marafioti T, et al. MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma. Int J Cancer. 2007;121(5):1156–1161. doi:10.1002/ijc.2280017487835
   PubMed Web of Science ®Google Scholar
• Montes-Moreno S, Martinez N, Sanchez-Espiridión B, et al. MiRNA expression in diffuse large B-cell lymphoma treated with chemoimmunotherapy. Blood. 2011;118(4):1034–1040. doi:10.1182/blood-2010-11-32155421633089
   PubMed Web of Science ®Google Scholar
• Rai D, Karanti S, Jung I, Dahia PL, Aguiar RC. Coordinated expression of microRNA-155 and predicted target genes in diffuse large B-cell lymphoma. Cancer Genet Cytogenet. 2008;181(1):8–15. doi:10.1016/j.cancergencyto.2007.10.00818262046
   PubMedGoogle Scholar
• Wu PY, Zhang XD, Zhu J, Guo XY, Wang JF. Low expression of microRNA-146b-5p and microRNA-320d predicts poor outcome of large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone. Hum Pathol. 2014;45(8):1664–1673. doi:10.1016/j.humpath.2014.04.00224931464
   PubMed Web of Science ®Google Scholar
• Clausen MR, Maurer MJ, Ulrichsen SP, et al. Pretreatment hemoglobin adds prognostic information to the NCCN-IPI in patients with diffuse large B-cell lymphoma treated with anthracycline-containing chemotherapy. Clin Epidemiol. 2019;11:987–996. doi:10.2147/CLEP.S21959531814771
   PubMed Web of Science ®Google Scholar
• Wu X, Wang F, Li Y, et al. Evaluation of latent membrane protein 1 and microRNA-155 for the prognostic prediction of diffuse large B cell lymphoma. Oncol Lett. 2018;15(6):9725–9734. doi:10.3892/ol.2018.856029844839
   PubMed Web of Science ®Google Scholar
• Berglund M, Hedström G, Amini RM, Enblad G, Thunberg U. High expression of microRNA-200c predicts poor clinical outcome in diffuse large B-cell lymphoma. Oncol Rep. 2013;29(2):720–724. doi:10.3892/or.2012.217323232598
   PubMed Web of Science ®Google Scholar
• Alencar AJ, Malumbres R, Kozloski GA, et al. MicroRNAs are independent predictors of outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Clin Cancer Res. 2011;17(12):4125–4135. doi:10.1158/1078-0432.CCR-11-022421525173
   PubMed Web of Science ®Google Scholar
• Ni H, Wang X, Liu H, Tian F, Song G. Low expression of miRNA-224 predicts poor clinical outcome in diffuse large B-cell lymphoma treated with R-CHOP. Biomarkers. 2015;20(4):253–257. doi:10.3109/1354750X.2015.106885526301883
   PubMed Web of Science ®Google Scholar
• Marques SC, Ranjbar B, Laursen MB, et al. High miR-34a expression improves response to doxorubicin in diffuse large B-cell lymphoma. Exp Hematol. 2016;44(4):238–246. doi:10.1016/j.exphem.2015.12.00726854484
   PubMed Web of Science ®Google Scholar
• Yang JM, Jang JY, Jeon YK, Paik JH. Clinicopathologic implication of microRNA-197 in diffuse large B cell lymphoma. J Transl Med. 2018;16(1):162. doi:10.1186/s12967-018-1537-029890998
   PubMedGoogle Scholar
• Troppan K, Wenzl K, Pichler M, et al. MiR-199a and miR-497 are associated with better overall survival due to increased chemosensitivity in diffuse large B-Cell lymphoma patients. Int J Mol Sci. 2015;16(8):18077–18095. doi:10.3390/ijms16081807726251897
   PubMed Web of Science ®Google Scholar
• Bai H, Wei J, Deng C, Yang X, Wang C, Xu R. MicroRNA-21 regulates the sensitivity of diffuse large B-cell lymphoma cells to the CHOP chemotherapy regimen. Int J Hematol. 2013;97(2):223–231. doi:10.1007/s12185-012-1256-x23275230
   PubMed Web of Science ®Google Scholar
• Zhang Y, Guo CC, Guan DH, Yang CH, Jiang YH. Prognostic value of microRNA-224 in various cancers: a meta-analysis. Arch Med Res. 2017;48(5):472–482. doi:10.1016/j.arcmed.2017.11.00229133193
   PubMed Web of Science ®Google Scholar
• Leivonen SK, Icay K, Jäntti K, et al. MicroRNAs regulate key cell survival pathways and mediate chemosensitivity during progression of diffuse large B-cell lymphoma. Blood Cancer J. 2017;7(12):654. doi:10.1038/s41408-017-0033-829242506
   PubMedGoogle Scholar
• Kim J, Jeong D, Nam J, et al. MicroRNA-124 regulates glucocorticoid sensitivity by targeting phosphodiesterase 4B in diffuse large B cell lymphoma. Gene. 2015;558(1):173–180. doi:10.1016/j.gene.2015.01.00125576220
   PubMed Web of Science ®Google Scholar
• Yuan WX, Gui YX, Na WN, Chao J, Yang X. Circulating microRNA-125b and microRNA-130a expression profiles predict chemoresistance to R-CHOP in diffuse large B-cell lymphoma patients. Oncol Lett. 2016;11(1):423–432. doi:10.3892/ol.2015.386626870228
   PubMed Web of Science ®Google Scholar
• Sun N, Wang CY, Sun YQ, et al. Down-regulated miR-148b increases resistance to CHOP in diffuse large B-cell lymphoma cells by rescuing Ezrin. Biomed Pharmacother. 2018;106:267–274. doi:10.1016/j.biopha.2018.06.09329966970
   PubMed Web of Science ®Google Scholar
• Feng Y, Zhong M, Zeng S, et al. Exosome-derived miRNAs as predictive biomarkers for diffuse large B-cell lymphoma chemotherapy resistance. Epigenomics. 2019;11(1):35–51. doi:10.2217/epi-2018-012330211623
   PubMed Web of Science ®Google Scholar
• Imig J, Motsch N, Zhu JY, et al. MicroRNA profiling in Epstein-Barr virus-associated B-cell lymphoma. Nucleic Acids Res. 2011;39(5):1880–1893. doi:10.1093/nar/gkq104321062812
   PubMed Web of Science ®Google Scholar
• Rahadiani N, Takakuwa T, Tresnasari K, Morii E, Aozasa K. Latent membrane protein-1 of Epstein-Barr virus induces the expression of B-cell integration cluster, a precursor form of microRNA-155, in B lymphoma cell lines. Biochem Biophys Res Commun. 2008;377(2):579–583. doi:10.1016/j.bbrc.2008.10.00718926796
   PubMed Web of Science ®Google Scholar
• Wood CD, Carvell T, Gunnell A, Ojeniyi OO, Osborne C, West MJ. Enhancer control of microRNA miR-155 expression in Epstein-Barr virus-infected B cells. J Virol. 2018;92(19):e00716–e00718. doi:10.1128/JVI.00716-1830021904
   PubMed Web of Science ®Google Scholar
• Zheng Z, Sun R, Zhao HJ, et al. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+ T cells. Mol Cancer. 2019;18(1):54. doi:10.1186/s12943-019-0977-330925928
   PubMedGoogle Scholar
• Andrade TA, Evangelista AF, Campos AH, et al. A microRNA signature profile in EBV+ diffuse large B-cell lymphoma of the elderly. Oncotarget. 2014;5(23):11813–11826. doi:10.18632/oncotarget.295225544772
   PubMedGoogle Scholar
• Re A, Cattaneo C, Rossi G. Hiv and lymphoma: from epidemiology to clinical management. Mediterr J Hematol Infect Dis. 2019;11(1):e2019004. doi:10.4084/MJHID.2019.00430671210
   PubMed Web of Science ®Google Scholar
• Thapa DR, Li X, Jamieson BD, Martínez-Maza O. Overexpression of microRNAs from the miR-17-92 paralog clusters in AIDS-related non-Hodgkin’s lymphomas. PLoS One. 2011;6(6):e20781. doi:10.1371/journal.pone.002078121698185
   PubMed Web of Science ®Google Scholar
• Thapa DR, Hussain SK, Tran WC, et al. Serum microRNAs in HIV-infected individuals as pre-diagnosis biomarkers for AIDS-NHL. J Acquir Immune Defic Syndr. 2014;66(2):229–237. doi:10.1097/QAI.000000000000014624675587
   PubMed Web of Science ®Google Scholar
• Vannata B, Arcaini L, Zucca E. Hepatitis C virus-associated B-cell non-Hodgkin’s lymphomas: what do we know? Ther Adv Hematol. 2016;7(2):94–107. doi:10.1177/204062071562392427054025
   PubMed Web of Science ®Google Scholar
• Augello C, Gianelli U, Savi F, et al. MicroRNA as potential biomarker in HCV-associated diffuse large B-cell lymphoma. J Clin Pathol. 2014;67(8):697–701. doi:10.1136/jclinpath-2014-20235224914240
   PubMed Web of Science ®Google Scholar
• Lasda E, Parker R. Circular RNAs: diversity of form and function. RNA. 2014;20(12):1829–1842. doi:10.1261/rna.047126.11425404635
   PubMed Web of Science ®Google Scholar
• Wang F, Nazarali AJ, Circular JS. RNAs as potential biomarkers for cancer diagnosis and therapy. Am J Cancer Res. 2016;6(6):1167–1176.27429839
   PubMed Web of Science ®Google Scholar
• Jeck WR, Sorrentino JA, Wang K, et al. Circular RNAs are abundant, conserved, and associated with ALU repeats. RNA. 2013;19(2):141–157. doi:10.1261/rna.035667.11223249747
   PubMed Web of Science ®Google Scholar
• Memczak S, Jens M, Elefsinioti A, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature. 2013;495(7441):333–338. doi:10.1038/nature1192823446348
   PubMed Web of Science ®Google Scholar
• Suzuki H, Tsukahara T. A view of pre-mRNA splicing from RNase R resistant RNAs. Int J Mol Sci. 2014;15(6):9331–9342. doi:10.3390/ijms1506933124865493
   PubMed Web of Science ®Google Scholar
• Danan M, Schwartz S, Edelheit S, Sorek R. Transcriptome-wide discovery of circular RNAs in Archaea. Nucleic Acids Res. 2011;40:3131–3142. doi:10.1093/nar/gkr100922140119
   PubMed Web of Science ®Google Scholar
• Nicolet BP, Engels S, Aglialoro F, van den Akker E, von Lindern M, Wolkers MC. Circular RNA expression in human hematopoietic cells is widespread and cell-type specific. Nucleic Acids Res. 2018;46(16):8168–8180. doi:10.1093/nar/gky72130124921
   PubMed Web of Science ®Google Scholar
• Hu Y, Zhao Y, Shi C, et al. A circular RNA from APC inhibits the proliferation of diffuse large B-cell lymphoma by inactivating Wnt/β-catenin signaling via interacting with TET1 and miR-888. Aging. 2019;11(19):8068–8084. doi:10.18632/aging.10212231631067
   PubMedGoogle Scholar
• Zhong Y, Du Y, Yang X, et al. Circular RNAs function as ceRNAs to regulate and control human cancer progression. Mol Cancer. 2018;17(1):79. doi:10.1186/s12943-018-0827-829626935
   PubMed Web of Science ®Google Scholar
• Kristensen LS, Hansen TB, Venø MT, Kjems J. Circular RNAs in cancer: opportunities and challenges in the field. Oncogene. 2018;37:555–565. doi:10.1038/onc.2017.36128991235
   PubMed Web of Science ®Google Scholar
• Geng Y, Jiang J, Wu C. Function and clinical significance of circRNAs in solid tumors. J Hematol Oncol. 2018;11(1):98. doi:10.1186/s13045-018-0643-z30064463
   PubMed Web of Science ®Google Scholar
• Jahani S, Nazeri E, Majidzadeh-A K, Jahani M, Esmaeili R. Circular RNA; a new biomarker for breast cancer: A systematic review. J Cell Physiol. 2020;235(7–8):5501–5510. doi:10.1002/jcp.2955831985056
   PubMed Web of Science ®Google Scholar
• Zhang C, Ma L, Niu Y, et al. Circular RNA in lung cancer research: biogenesis, functions, and roles. Int J Biol Sci. 2020;16(5):803–814. doi:10.7150/ijbs.3921232071550
   PubMed Web of Science ®Google Scholar
• Hao S, Cong L, Qu R, Liu R, Zhang G, Li Y. Emerging roles of circular RNAs in colorectal cancer. Onco Targets Ther. 2019;12:4765–4777. doi:10.2147/OTT.S20823531354303
   PubMed Web of Science ®Google Scholar
• Dahl M, Daugaard I, Andersen MS, et al. Enzyme-free digital counting of endogenous circular RNA molecules in B-cell malignancies. Lab Invest. 2018;98(12):1657–1669. doi:10.1038/s41374-018-0108-630087459
   PubMed Web of Science ®Google Scholar
• Caley DP, Pink RC, Trujillano D, Carter DR. Long noncoding RNAs, chromatin, and development. Sci World J. 2010;10:90–102. doi:10.1100/tsw.2010.7
   Google Scholar
• Fatima R, Akhade VS, Pal D, Rao SM. Long noncoding RNAs in development and cancer: potential biomarkers and therapeutic targets. Mol Cell Ther. 2015;3:5. doi:10.1186/s40591-015-0042-626082843
   PubMedGoogle Scholar
• Wang FY, Gu ZY, Gao CJ. Emerging role of long non-coding RNAs in normal and malignant hematopoiesis. Chin Med J. 2020;133(4):462–473. doi:10.1097/CM9.000000000000062431904731
   PubMed Web of Science ®Google Scholar
• Tayari MM, Winkle M, Kortman G, et al. Long noncoding RNA expression profiling in normal B-cell subsets and hodgkin lymphoma reveals Hodgkin and Reed-Sternberg cell-specific long noncoding RNAs. Am J Pathol. 2016;186(9):2462–2472. doi:10.1016/j.ajpath.2016.05.01127423697
   PubMed Web of Science ®Google Scholar
• Verma A, Jiang Y, Du W, Fairchild L, Melnick A, Elemento O. Transcriptome sequencing reveals thousands of novel long non-coding RNAs in B cell lymphoma. Genome Med. 2015;7:110. doi:10.1186/s13073-015-0230-726521025
   PubMed Web of Science ®Google Scholar
• Gao HY, Wu B, Yan W, et al. Microarray expression profiles of long non-coding RNAs in germinal center-like diffuse large B-cell lymphoma. Oncol Rep. 2017;38(3):1363–1372. doi:10.3892/or.2017.582128713985
   PubMed Web of Science ®Google Scholar
• Zhu D, Fang C, Li X, et al. Predictive analysis of longnon-coding RNA expression profifiles in diffuse large B cell lymphoma. Oncotarget. 2017;8(14):23228–23236. doi:10.18632/oncotarget.1557128423571
   PubMedGoogle Scholar
• Dousti F, Shahrisa A, Ansari H, et al. Long non-coding RNAs expression levels in diffuse large B-cell lymphoma: an in silico analysis. Pathol Res Pract. 2018;214(9):1462–1466. doi:10.1016/j.prp.2018.08.00630104077
   PubMed Web of Science ®Google Scholar
• Fatica A, Bozzoni I. Long non-coding RNAs: new players in cell differentiation and development. Nat Rev Genet. 2014;15(1):7–21. doi:10.1038/nrg360624296535
   PubMed Web of Science ®Google Scholar
• Wang QM, Lian GY, Song Y, Huang YF, Gong Y. LncRNA MALAT1 promotes tumorigenesis and immune escape of diffuse large B cell lymphoma by sponging miR-195. Life Sci. 2019;231:116335. doi:10.1016/j.lfs.2019.03.04030898647
   PubMed Web of Science ®Google Scholar
• Zhao L, Liu Y, Zhang J, Liu Y, Qi Q. LncRNA SNHG14/miR-5590-3p/ZEB1 positive feedback loop promoted diffuse large B cell lymphoma progression and immune evasion through regulating PD-1/PD-L1 checkpoint. Cell Death Dis. 2019;10(10):731. doi:10.1038/s41419-019-1886-531570691
   PubMed Web of Science ®Google Scholar
• Zhu Q, Li Y, Guo Y, et al. Long non-coding RNA SNHG16 promotes proliferation and inhibits apoptosis of diffuse large B-cell lymphoma cells by targeting miR-497-5p/PIM1 axis. J Cell Mol Med. 2019;23(11):7395–7405. doi:10.1111/jcmm.1460131483572
   PubMed Web of Science ®Google Scholar
• Chen LY, Zhang XM, Han BQ, Dai HB. Long noncoding RNA SNHG12 indicates the prognosis and accelerates tumorigenesis of diffuse large B-Cell lymphoma through sponging microR-195. Onco Targets Ther. 2020;13:5563–5574. doi:10.2147/OTT.S24942932606771
   PubMed Web of Science ®Google Scholar
• Deng L, Jiang L, Tseng KF, et al. Aberrant NEAT1_1 expression may be a predictive marker of poor prognosis in diffuse large B cell lymphoma. Cancer Biomark. 2018;23(2):157–164. doi:10.3233/CBM-16022130175971
   PubMed Web of Science ®Google Scholar
• Peng W, Feng J. Long noncoding RNA LUNAR1 associates with cell proliferation and predicts a poor prognosis in diffuse large B-cell lymphoma. Biomed Pharmacother. 2016;77:65–71. doi:10.1016/j.biopha.2015.12.00126796267
   PubMed Web of Science ®Google Scholar
• Peng W, Wu J, Feng J. Long noncoding RNA HULC predicts poor clinical outcome and represents pro-oncogenic activity in diffuse large B-cell lymphoma. Biomed Pharmacother. 2016;79:188–193. doi:10.1016/j.biopha.2016.02.03227044827
   PubMed Web of Science ®Google Scholar
• Peng W, Wu J, Feng J. LincRNA-p21 predicts favorable clinical outcome and impairs tumorigenesis in diffuse large B cell lymphoma patients treated with R-CHOP chemotherapy. Clin Exp Med. 2017;17(1):1–8. doi:10.1007/s10238-015-0396-826475621
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang M, Xu H, et al. Discovery and validation of the tumor-suppressive function of long noncoding RNA PANDA in human diffuse large B-cell lymphoma through the inactivation of MAPK/ERK signaling pathway. Oncotarget. 2017;8(42):72182–72196. doi:10.18632/oncotarget.2005329069778
   PubMedGoogle Scholar
• Yan Y, Han J, Li Z, Yang H, Sui Y, Wang M. Elevated RNA expression of long non-coding HOTAIR promotes cell proliferation and predicts a poor prognosis in patients with diffuse large B cell lymphoma. Mol Med Rep. 2016;13(6):5125–5131. doi:10.3892/mmr.2016.519027122348
   PubMed Web of Science ®Google Scholar
• Zhao CC, Jiao Y, Zhang YY, et al. Lnc SMAD5-AS1 as ceRNA inhibit proliferation of diffuse large B cell lymphoma via Wnt/β-catenin pathway by sponging miR-135b-5p to elevate expression of APC. Cell Death Dis. 2019;10(4):252. doi:10.1038/s41419-019-1479-330874550
   PubMed Web of Science ®Google Scholar
• Shi X, Cui Z, Liu X, et al. LncRNA FIRRE is activated by MYC and promotes the development of diffuse large B-cell lymphoma via Wnt/β-catenin signaling pathway. Biochem Biophys Res Commun. 2019;510(4):594–600. doi:10.1016/j.bbrc.2019.01.10530739786
   PubMed Web of Science ®Google Scholar
• Meng H, Zhao B, Wang Y. FOXM1-induced upregulation of lncRNA OR3A4 promotes the progression of diffuse large B-cell lymphoma via Wnt/β-catenin signaling pathway. Exp Mol Pathol. 2020;115:104451. doi:10.1016/j.yexmp.2020.10445132417392
   PubMed Web of Science ®Google Scholar
• Peng W, Fan H, Wu G, Wu J, Feng J. Upregulation of long noncoding RNA PEG10 associates with poor prognosis in diffuse large B cell lymphoma with facilitating tumorigenicity. Clin Exp Med. 2016;16(2):177–182. doi:10.1007/s10238-015-0350-925864113
   PubMed Web of Science ®Google Scholar
• Zhou M, Zhao H, Xu W, Bao S, Cheng L, Sun J. Discovery and validation of immune-associated long non-coding RNA biomarkers associated with clinically molecular subtype and prognosis in diffuse large B cell lymphoma. Mol Cancer. 2017;16(1):16. doi:10.1186/s12943-017-0580-428103885
   PubMedGoogle Scholar
• Zhao S, Fang S, Liu Y, et al. The long non-coding RNA NONHSAG026900 predicts prognosis as a favorable biomarker in patients with diffuse large B-cell lymphoma. Oncotarget. 2017;8(21):34374–34386. doi:10.18632/oncotarget.1616328423735
   PubMedGoogle Scholar
• Sun J, Cheng L, Shi H, et al. A potential panel of six-long non-coding RNA signature to improve survival prediction of diffuse large-B-cell lymphoma. Sci Rep. 2016;6:27842. doi:10.1038/srep2784227292966
   PubMed Web of Science ®Google Scholar